MCID: BSL008
MIFTS: 48

Basal Ganglia Disease

Categories: Neuronal diseases

Aliases & Classifications for Basal Ganglia Disease

MalaCards integrated aliases for Basal Ganglia Disease:

Name: Basal Ganglia Disease 12 15 17
Basal Ganglia Diseases 77 45 74
Abnormality of the Basal Ganglia 6
Basal Ganglia Disorders 56

Classifications:



External Ids:

Disease Ontology 12 DOID:679
MeSH 45 D001480
SNOMED-CT 69 70835005
UMLS 74 C0004782

Summaries for Basal Ganglia Disease

Disease Ontology : 12 A brain disease that is characterized by dysfunctional movement, located in basal ganglia with_material basis in diseased components of the basal ganglia and associated neural circuits.

MalaCards based summary : Basal Ganglia Disease, also known as basal ganglia diseases, is related to thiamine metabolism dysfunction syndrome 2 and basal ganglia calcification. An important gene associated with Basal Ganglia Disease is IFIH1 (Interferon Induced With Helicase C Domain 1), and among its related pathways/superpathways are NRF2 pathway and Vemurafenib Pathway, Pharmacodynamics. The drugs Zonisamide and Apomorphine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and subthalamic nucleus, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 77 Basal ganglia disease is a group of physical problems that occur when the group of nuclei in the brain... more...

Related Diseases for Basal Ganglia Disease

Diseases related to Basal Ganglia Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 28, show less)
# Related Disease Score Top Affiliating Genes
1 thiamine metabolism dysfunction syndrome 2 33.8 SLC19A3 SLC5A6
2 basal ganglia calcification 30.4 PDGFB PDGFRB SLC20A2 THAP1 XPR1
3 dystonia 29.6 FTL SLC19A3 SLC20A2 THAP1
4 biotin-thiamine-responsive basal ganglia disease 12.8
5 dandy-walker malformation with intellectual disability, basal ganglia disease and seizures 12.7
6 infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome 12.3
7 pettigrew syndrome 12.3
8 early-onset parkinsonism-intellectual disability syndrome 12.1
9 neurodegeneration with brain iron accumulation 3 12.0
10 encephalopathy due to defective mitochondrial and peroxisomal fission 2 11.3
11 neurodegeneration with brain iron accumulation 8 11.1
12 biotin deficiency 10.2 SLC19A3 SLC5A6
13 waisman syndrome 10.0
14 dandy-walker complex 10.0
15 liver cirrhosis 9.9
16 focal hand dystonia 9.9 PDGFB THAP1
17 hereditary ataxia 9.9
18 stiff-person syndrome 9.9
19 leigh syndrome 9.9
20 dystonia 3, torsion, x-linked 9.9
21 alacrima, achalasia, and mental retardation syndrome 9.9
22 hemiplegia 9.9
23 neuroleptic malignant syndrome 9.9
24 depression 9.9
25 encephalopathy 9.9
26 connective tissue benign neoplasm 9.6 PDGFRB PTH
27 hypophosphatemic rickets with hypercalciuria, hereditary 9.6 PTH SLC20A2
28 primary familial brain calcification 9.4 PDGFB PDGFRB SLC20A2 XPR1

Graphical network of the top 20 diseases related to Basal Ganglia Disease:



Diseases related to Basal Ganglia Disease

Symptoms & Phenotypes for Basal Ganglia Disease

MGI Mouse Phenotypes related to Basal Ganglia Disease:

47 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 ADORA2A AP1S2 CRAT IFIH1 PDGFB PDGFRB
2 homeostasis/metabolism MP:0005376 9.96 ADORA2A AP1S2 CRAT IFIH1 PDGFB PDGFRB
3 cardiovascular system MP:0005385 9.91 ADORA2A CRAT PDGFB PDGFRB PTH SLC20A2
4 immune system MP:0005387 9.81 ADORA2A IFIH1 PDGFB PDGFRB PTH SLC19A3
5 liver/biliary system MP:0005370 9.43 IFIH1 PDGFB SLC19A3 SLC20A2 SLC5A6 THAP1
6 nervous system MP:0003631 9.23 ADORA2A AP1S2 PDGFB PDGFRB SLC19A3 SLC20A2

Drugs & Therapeutics for Basal Ganglia Disease

Drugs for Basal Ganglia Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 592, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
2
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-00-4, 41372-20-7 6005
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
4
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
5
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
6
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136236-51-6 3052776
7
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
8
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 120014-06-4 3152
9
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
10
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104632-26-0 119570 59868
11
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
12
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 768-94-5 2130
13
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
14
Clonidine Approved Phase 4,Phase 2,Not Applicable 4205-90-7 2803
15
Tetrabenazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-46-8 6018
16
Droxidopa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23651-95-8 443940
17
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28860-95-9 34359
18
Rotigotine Approved Phase 4,Phase 3,Phase 2,Phase 1 99755-59-6, 92206-54-7 57537
19
Opicapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 923287-50-7
20
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
21
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130929-57-6 5281081
22
Levetiracetam Approved, Investigational Phase 4,Phase 2 102767-28-2 441341
23
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
24
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
25
Modafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
26
Risperidone Approved, Investigational Phase 4,Phase 2,Not Applicable 106266-06-2 5073
27
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
28
Galantamine Approved Phase 4,Phase 3,Not Applicable 357-70-0 9651
29
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
30
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 57808-66-9 3151
31
Benserazide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 322-35-0
32
Mirabegron Approved Phase 4 223673-61-8 9865528
33
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 5311068 68602
34
Bromocriptine Approved, Investigational Phase 4,Phase 3,Not Applicable 25614-03-3 31101
35
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Not Applicable 68-04-2
36
Trimethobenzamide Approved, Investigational Phase 4,Phase 1 138-56-7 5577
37
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
38
Lubiprostone Approved, Investigational Phase 4,Not Applicable 136790-76-6 656719
39
Selegiline Approved, Investigational, Vet_approved Phase 4,Not Applicable 14611-51-9 5195 26757
40
Methylphenidate Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 113-45-1 4158
41
Cabergoline Approved Phase 4,Phase 3,Not Applicable 81409-90-7 54746
42
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
43
Riluzole Approved, Investigational Phase 4,Phase 3,Phase 2 1744-22-5 5070
44
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7440-66-6 32051
45
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
46
Sulfamethazine Approved, Investigational, Vet_approved Phase 4,Not Applicable 57-68-1 5327
47
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Early Phase 1 147-24-0, 58-73-1 3100
48
Promethazine Approved, Investigational Phase 4,Phase 2,Early Phase 1 60-87-7 4927
49
Suvorexant Approved, Investigational Phase 4 1030377-33-3
50
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
51
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
52
Ondansetron Approved Phase 4 99614-02-5 4595
53
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
54
Infliximab Approved Phase 4 170277-31-3
55
Penicillamine Approved Phase 4,Phase 3,Early Phase 1 52-67-5 4727 5852
56
Zoledronic Acid Approved Phase 4 118072-93-8 68740
57
Idebenone Approved, Investigational Phase 4 58186-27-9
58
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
59
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 73-31-4 896
60
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 77-92-9 311
61
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2 56-86-0 33032
62
Serine Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1 56-45-1 5951
63
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
64
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 1406-16-2
65
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
66
Imidazole Experimental, Investigational Phase 4 288-32-4 795
67
Corticosterone Experimental Phase 4 50-22-6 5753
68 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
69 calcium channel blockers Phase 4,Phase 2,Phase 3
70 Calcium, Dietary Phase 4,Phase 2,Phase 3,Not Applicable
71 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
72 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
73 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
74 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
75 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
76 Emetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
77 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
78 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
79 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
80 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
81 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
82 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
83 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
84 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
85 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
86 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
87 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
88 Dihydroxyphenylalanine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
89 Cardiotonic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
90 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
91 Monoamine Oxidase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
92 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
93 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
94 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
95 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
96 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
97 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
98 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
99 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
100 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
101 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
102 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
103 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
104 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
105 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
106 Nicotinic Agonists Phase 4,Phase 2,Phase 1,Not Applicable
107 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
108 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
109 Sympatholytics Phase 4,Phase 2,Not Applicable
110 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
111 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
112 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
113 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
114 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
115 Catechol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
116 Catechol O-Methyltransferase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
117 Anesthetics, Intravenous Phase 4,Phase 2,Not Applicable
118 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
119 Anesthetics, General Phase 4,Phase 2,Not Applicable
120 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
121 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
122 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
123 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
124 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
125 Carbidopa, levodopa drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
126 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
127 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
128 Quetiapine Fumarate Phase 4,Not Applicable 111974-72-2
129 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
130 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
131 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
132 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
133 Narcotic Antagonists Phase 4,Phase 3,Phase 2
134 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
135 Wakefulness-Promoting Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
136 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
137 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
138 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
139 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
140 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
141 cadexomer iodine Phase 4,Phase 2
142 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
143 Nutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
144 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
145 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
146 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
147 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
148 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
149 cysteine Phase 4,Phase 1,Not Applicable
150 Soy Bean Phase 4
151 Whey Protein Phase 4,Not Applicable
152 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
153 Dopamine Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
154 Dopa Decarboxylase Phase 4,Phase 3,Phase 2,Phase 1
155 Benserazide, levodopa drug combination Phase 4,Phase 2,Phase 3,Phase 1
156 Adrenergic beta-3 Receptor Agonists Phase 4
157 Adrenergic beta-Agonists Phase 4,Not Applicable
158 Talipexole Phase 4 101626-70-4
159 Sildenafil Citrate Phase 4,Phase 2,Not Applicable 171599-83-0
160 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
161 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
162 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Not Applicable
163 Citrate Phase 4,Phase 2,Not Applicable
164 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
165 Parasympatholytics Phase 4,Phase 2,Phase 3,Not Applicable
166 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
167 Solifenacin succinate Phase 4,Phase 3 242478-38-2
168 Dopamine Uptake Inhibitors Phase 4,Phase 2,Not Applicable,Early Phase 1
169 Duloxetine Hydrochloride Phase 4,Phase 3,Phase 2
170 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3,Phase 2
171 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
172 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
173 Excitatory Amino Acid Agonists Phase 4,Phase 1
174 Antipruritics Phase 4,Phase 3,Phase 1,Phase 2
175 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
176 Trientine Phase 4,Phase 3,Phase 1,Not Applicable
177 Antidotes Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
178 Fluorodeoxyglucose F18 Phase 4,Phase 2
179 Bone Density Conservation Agents Phase 4,Phase 2,Not Applicable
180 Ubiquinone Phase 4,Phase 2,Phase 3,Phase 1
181 Ergocalciferols Phase 4,Phase 2
182 Vitamin D2 Phase 4,Phase 2
183 Calciferol Phase 4,Phase 2,Not Applicable
184 Orexin Receptor Antagonists Phase 4
185 Natriuretic Agents Phase 4,Phase 2,Phase 1
186 Vasopressins Phase 4,Phase 1,Phase 2
187 Arginine Vasopressin Phase 4,Phase 1,Phase 2
188 Calamus Phase 4,Not Applicable
189 Hemostatics Phase 4
190 arginine Phase 4
191 Coagulants Phase 4
192 Deamino Arginine Vasopressin Phase 4
193
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-67-9 5202
194
Carbon monoxide Approved, Investigational Phase 3 630-08-0 281
195
Cysteamine Approved, Investigational Phase 2, Phase 3 60-23-1 6058
196
Dronabinol Approved, Illicit Phase 3,Phase 2 1972-08-3 16078
197
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
198
Deferiprone Approved Phase 3,Phase 2,Not Applicable 30652-11-0 2972
199
Hydroxocobalamin Approved Phase 2, Phase 3,Not Applicable 13422-51-0 15589840 11953898
200
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Not Applicable 13422-55-4
201
Pimavanserin Approved, Investigational Phase 3,Phase 2 706779-91-1 16058810
202
Fluoxetine Approved, Vet_approved Phase 3,Phase 2 54910-89-3 3386
203
Paroxetine Approved, Investigational Phase 3,Phase 2 61869-08-7 43815
204
Adenosine Approved, Investigational Phase 3,Phase 2,Phase 1 58-61-7 60961
205
Rifaximin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 80621-81-4 46783403 6436173
206
Caffeine Approved Phase 3,Phase 2 58-08-2 2519
207
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
208
Oxycodone Approved, Illicit, Investigational Phase 3,Phase 2 76-42-6 5284603
209
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 6251 453